Clinical Report: Checkmate 214 9-Year Results in Metastatic Kidney Cancer
Overview
The 9-year follow-up of the CHECKMATE-214 trial demonstrates that over 30% of patients with metastatic kidney cancer are still alive after treatment with nivolumab and ipilimumab. This marks a significant improvement in long-term survival compared to historical data, with no new toxicities reported.
Background
The CHECKMATE-214 trial has been pivotal in establishing immunotherapy as a viable treatment option for metastatic kidney cancer. Prior to these advancements, the 5-year survival rate for this patient population was only 5%. The long-term results from this trial provide crucial insights into the durability and safety of immunotherapy in this setting.
Data Highlights
| Outcome | Nivolumab + Ipilimumab | Sunitinib |
|---|---|---|
| 9-Year Overall Survival | 31% | 20% |
| 108-Month OS (Intermediate/Poor Risk) | 30% | 19% |
| 96-Month PFS | 23% | 9% |
Key Findings
- Over 30% of patients treated with nivolumab and ipilimumab are alive at 9 years.
- Median overall survival improved to 53 months for nivolumab/ipilimumab versus 38 months for sunitinib.
- Long-term safety was confirmed with no new toxicities reported.
- Durability of responses was significantly higher in the nivolumab/ipilimumab group compared to sunitinib.
- Long-term progression-free survival (PFS) favored the immunotherapy combination.
Clinical Implications
The findings from the CHECKMATE-214 trial underscore the importance of immunotherapy as a first-line treatment for metastatic kidney cancer. Clinicians can now provide patients with more optimistic long-term survival expectations and emphasize the durability of treatment responses.
Conclusion
The 9-year results from CHECKMATE-214 represent a significant advancement in the treatment of metastatic kidney cancer, reinforcing the role of nivolumab and ipilimumab as a standard of care.
References
- Choueiri, T.K., ASCO 2025 -- CheckMate 214 Shows Long-Term OS, PFS Benefit With Nivolumab plus Ipilimumab in RCC
- Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research, Dana-Farber
- EAU Guidelines on Renal Cell Carcinoma 2025
- Ophthalmology Management — Viewpoint
- philips image guided therapy devices academy — Live case broadcast; Complex coronary PCI strategies
- The ASCO Post — Endangered Art of Medicine
- ASCO 2025: CheckMate 214 Shows Long-Term OS, PFS Benefit With Nivolumab plus Ipilimumab in RCC | Cancer Nursing Today
- https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Renal-Cell-Carcinoma-2025.pdf
- Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial | Nature Medicine
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
